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Abstract Plasmacytoid dendritic cells (pDCs) are bone marrow-derived immune cells with the
ability to express copious amounts of type I and III interferon (IFN) and can differentiate into
antigen-presenting dendritic cells as a result of stimulation by pathogen-derived nucleic acid.
These powerful combined functionalities allow pDCs to bridge the innate and adaptive immune
systems resulting in a concerted pathogen response. The contribution of pDCs to gastrointestinal
immunity is only now being elucidated and is proving to be a critical component in systemic
immunity. This review will explore the immunology of pDCs and will discuss their involvement in
human disease and tolerance with an emphasis on those in the gastrointestinal lymphoid tissue.
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1.1. Note from the authors
Since the identification of pDCs as a discrete class of immune
cells, significant progress has been made in understanding
their developmental process and the mechanisms by which
they respond to pathogens. Although we will briefly discuss
these subjects, the primary purpose of this review is to
emphasize the role of pDCs in gastrointestinal immunity and
gut-related pathology. Therefore, we would refer the reader
to a number of excellent reviews such as Reizis et al. [1],
Fitzgerald-Bocarsly et al. [2], or Lande and Gilliet [3], which
provide a comprehensive summary of the development and
mechanisms of pDC functionality.
1.2. Identification of pDCs as unique populations of
immune cells
Dendritic cells (DCs) are antigen-presenting cells that sense
pathogens and present pathogen-derived peptides to T and B
cells, thus triggering and influencing adaptive immune
responses. In humans, dendritic cells are most commonly
divided into two classes: plasmacytoid dendritic cells (pDCs)
and conventional dendritic cells (cDCs) [4,5]. cDCs can be
further subdivided into five populations based upon their
expression of the surface markers CD1c, CD16, or BDCA-3 [6].
Each subtype of cDC has been reported to display significant
transcriptional differences, likely reflective of their differ-
ences in antigen-uptake, signaling, and migration [7]. pDCs
are a unique population of bone-marrow-derived immune cells
that upon activation by pathogen-derived nucleic acid
produce large amounts of type I and type III IFN as well as
proinflammatory cytokines [8,9]. Accordingly, pDCs play a
pivotal role in bridging the innate and adaptive immune
systems. Although the first unequivocal characterization of
pDCs was relatively recent, Lennert and Remmele first
described pDCs in 1958 as a subset of cells with plasma
cell-like morphology observed in lymph nodes (LNs) [10]. In
consideration of their morphology, and their expression of the
T cell marker CD4 [11] and monocyte markers such as CD123
and CD68 [10,12], these cells came to be known as
plasmacytoid T cells or plasmacytoid monocytes. Twenty
years after Lennert and Remmele first described theplasmacytoid T cells, Trinchieri and colleagues identified a
subset of non-T cell lymphocytes by their antiviral activity and
their ability to activate natural killer (NK)-cell-mediated
cytotoxicity through the production of IFN-α [13]. Those cells
were subsequently referred to as natural IFN-producing cells.
Ultimately, independent research conducted in the laborato-
ries of Liu [14] and Colonna [8] confirmed that the
plasmacytoid T cells identified by Lennert and Remmele and
the natural IFN-producing cells identified by Trinchieri and
colleagues were one and the same.
2. Development, distribution and morphology
2.1. Classic dendritic cells vs. plasmacytoid
dendritic cells
pDCs share many key features with cDCs, to which they are
related; therefore, it is useful to use cDCs as a point of
reference when discussing pDCs. Both pDCs and cDCs originate
from a common hematopoietic progenitor and differentiate
through a pathway that involves FMS-related tyrosine kinase 3
(FLT3L)-induced signaling [15,16]. Although the two cell
populations may originate from a common bone marrow
precursor, pDCs diverge down an alternative developmental
path in a process that likely requires the constitutive
expression of the pDC-specific transcription factor E2-2 as
well as the Runt family transcription factor Runx2 [17–20].
The migration and distribution patterns also differ between
the two classes of dendritic cells. cDC precursors travel via the
bloodstream to the lymphoid organs and peripheral tissue
where they develop into immature resident and migratory
DCs, respectively [4]. These immature cDCs are committed to
antigen sampling and are characterized by low-level expres-
sion of T cell costimulatory molecules and major histocom-
patibility complex (MHC) class II [5]. They may remain in the
resident tissue until they encounter an activation signal,
typically as a result of the engagement of Toll-like receptors
(TLRs) [21]. TLRs are transmembrane receptors that recognize
repeatingmolecularmotifs conservedwithin a specific class of
microbe, such as the lipopolysaccharide of Gram-negative
bacteria or the unmethylated CpG DNA common to many
microbial genomes [22,23]. Upon microbial activation, these
immature cDCs will migrate to the LNs where they undergo
significant changes that result in the development of their
167mature phenotype [21]. In the absence of pathogen stimuli,
cDCs can migrate to the LNs under steady state condi-
tions [24], a property that is necessary to fulfill their
mandate in the presentation of self-antigens while estab-
lishing immune tolerance [25].2.2. Development, migratory properties and
morphology of pDCs
In contrast to the development and migratory properties of
cDCs, pDCs fully develop in the bonemarrow and subsequently
travel via the bloodstream to the thymus and all secondary
lymphoid organs through high endothelial venules under
steady-state conditions [26,27] in a process that is also
dependent on Runx2 as well as the CCR5 (CD195) receptor
[19]. Prior to stimulation by pathogen-derivedmolecules, fully
developed pDCs are often referred to as “pre-pDCs”[4] or
“resting” pDCs [28]. In the steady state, pDCs can migrate to
specific tissue such as the LNs or gut, under the control ofTable 1 Receptors and ligands of human plasmacytoid dendritic
Receptor Alt. name Ligand Lo
CD4 CD4 MHC II Ce
IL3RA CD123 Interleukin 3 (IL-3) Ce
BDCA-2 a CD303 C-type lectin Ce
ILT7 a CD85g BST2 Ce
LAMP4 CD68 Lectins or selectins En
B7-1 CD80 CD28 and CTLA-4 Ce
B7-2 CD86 CD28 and CTLA-4 Ce
TNFRSF5 CD40 CD154 (CD40L) Ce
FLT3 CD135 FLT3L Ce
Toll-like receptor 7 TLR-7 Single stranded RNA En
Toll-like receptor 9 TLR-9 CpG DNA En
RIG-I DDX58 dsRNA Cy
MDA-5 IFIH1 dsRNA Cy
CCR5 CD195 CCL5, CCL3, CCL4 Ce
CCR7 CD197 CCL19, CCL21 Ce
CCR9 CD199 CCL25 Ce
PKR EIF2AK2 dsRNA Cy
LY75 CD205 C-type lectin Ce
αEβ7 integrin CD103 E-cadherin Ce
β2 integrin CD18 ICAM-1, FHL2, PSCD1 Ce
α4β7 integrin LPAM-1 MadCAM-1 Ce
P-selectin CD62P P-selectin glycoprotein lig-1 Ce
CXCR4 CD184 CXCL12 Ce
TNFRSF13B CD267 TNFSF13, BAFF M
a Specific to pDCs.chemokine receptors including CCR7 (CD197) and CCR9
(CD199) and their corresponding ligands CCL19 (MIP-3β),
CCL21 (6Ckine), and CCL25 (TECK), respectively (Table 1)
[29–32]. This migration is essential for presentation of
self-antigens and thus for promotion of immune tolerance
[23,33,34]. Whereas cDCs migrate from sites of infection to
the LNs and subsequently activate naïve T cells, few pDCs
appear to do so and only in the late stages of infection [35].
pDCs are unique among immune cells in that they
occupy two discrete “professional” roles, one as effector
cells in consideration of their consummate production of
type I and type III IFN and the other as antigen-presenting
cells (APCs) [28]. These two specialized roles exist at
distinct functional stages that are characterized by
fundamentally different morphologies. Resting pDCs have a
morphology resembling antibody producing plasma cells, hence
the term “plasmacytoid”. Once activated, pDCs undergo pro-
found morphological and functional changes to transform from
IFN-producing cells into classical antigen-presenting dendritic
cells, capable of stimulating naïve T cells and possessing classiccells.
cation Function in pDCs
ll membrane Co-receptor, upregulated upon CpC
stimulation
ll membrane Promotes differentiation into cDCs
ll membrane C-type lectin receptor, IFN production
blocked by mAbs
ll membrane Negatively regulates pDC function, IFN
production blocked by mAb
dosomal memb. Tissue homing, promotes phagocytosis
ll membrane Co-stimulatory
ll membrane Co-stimulatory
ll membrane Co-stimulatory, activation, TD class switch
recombination
ll membrane Regulates hematopoiesis
dosomal memb. Induction of type I interferons
and proinflammatory cytokines
dosomal memb. Induction of type I interferons
and proinflammatory cytokines
tosolic Induction of type I interferons
and proinflammatory cytokines
tosolic Induction of type I interferons
and proinflammatory cytokines
ll membrane Gut homing
ll membrane LN homing
ll membrane Expressed on IE and LP
tosolic Innate immune response to viral infection
ll membrane Putative antigen uptake receptor
ll membrane Gut homing (upregulated in HIV infection)
ll membrane Gut homing, pairs with CD11a, b, c, and d
ll membrane Gut homing
ll membrane Gut homing
ll membrane Chemotatic receptor, co-receptor for HIV
embrane (B-cells) Ligands produced by pDCs, T-cell
independent IgA induction
168 V.C. Lombardi, S.F. Khaiboullinadendritic morphology. Human peripheral blood pDCs uniquely
express the blood dendritic cell antigen-2 (BDCA-2) (also called
CD303) and the immunoglobulin-like transcript 7 (ILT7) [36,37].
Additionally, they express CD4 and CD123, but lack expression
of CD14 [36]. In contrast, murine pDCs can be defined as
CD11cint CD45R/B220+ BST2/mPDCA-1+[27]. Recently, a sub-
class of human pDCs was reported to express the neural cell
adhesion molecule CD56, a common NK-cell marker, in
response to activation with adult tick-borne encephalitis
vaccine FSME [38]. The expression of CD56 was reported to
coincide with the presence of other cytotoxic molecules, such
as tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) and granzyme B. This observation suggests an
additional role for pDCs as cytolytic effector cells, indepen-
dent of their traditional rolls in type I IFN-production and
antigen presentation.
3. Activation and cytokine production through
Toll-like receptor engagement
3.1. Type I IFN and inflammatory cytokines
pDCs are the primary producers of type I IFN, having the
capacity to produce all isoforms, including IFN-β, IFN-ε, IFN-κ,
IFN-ω, and all 12 subtypes of IFN-α. Additionally, they have the
ability to produce a significant amount of the type III IFNs:
IFN-λ1 and -λ2 (also known as interleukin (IL)-29 and IL-28A,
respectively); however, they produce little if any IFN-λ3
(IL-28B) [39–43]. Although accounting for only 0.1 to 0.5% of
peripheral blood cells, pDCs are responsible for over 95% of type
I IFN produced by circulating lymphocytes [14], firmly estab-
lishing their key role as professional IFN-producing cells. In
addition to IFN, pDCs also have the ability to produce a number
of inflammatory cytokines and chemokines including IL-6,
TNF-α, CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CXCL8
(IL-8), and CXCL10 (IP-10) [44–46]. The production of IFN, as
well as inflammatory cytokines and chemokines, is a result of a
signaling cascade, which initiates through the engagement of
endosomally located TLR-7 and TLR-9, by single stranded RNA
[47,48] or non-methylated DNA and CpG oligodeoxynucleotides
(CpG-DNA) [49,50], respectively (Fig. 1). Similar to all other
TLRs (with the notable exception of TLR-3), TLR-7 and TLR-9
employ the universal adapter protein MyD88 (myeloid differen-
tiation primary response 88), which acts via NF-κB and IRF7, to
initiate transcription of inflammatory cytokines and IFN,
respectively (see Bao and Lius [51] for a comprehensive review
of TLR signaling and control in pDCs).
In addition to activation of TLR-7 and TLR-9 by ssRNA and
CpG DNA, respectively, pDCs are also reported to produce type I
IFN in response to dsRNA [45]. The production of IFN in response
to dsRNA, however, is unlikely to be related to TLR engagement
in that pDCs are reported to express little if any dsRNA-sensing
TLR-3 [52,53]. Previous studies attribute the ability of cDCs to
produce type I IFN in response to dsRNA through the
engagement of TLR-3 as well as through the cytosolic retinoic
acid-inducible gene (RIG)-like helicases RIG-I and melanoma
differentiation antigen 5 (MDA5) [54,55]. Kramer et al. reported
that human pDCs express RIG-I and MDA5 transcripts as well as
protein to a greater extent than that of cDCs, suggesting the
possibility of their involvement in dsRNA-triggered IFN produc-
tion [71]. However, using murine RIG-I knockout model, Katoand coworkers reported that RIG-I and MDA5 did not contribute
to the ability of pDCs to respond to dsRNA [55]. Additionally,
Ruscanu et al. reported that bluetongue virus, a dsRNA virus,
activated type I IFN in purified ovine pDCs in a TLR-7/
8-independent and MyD88-dependent manner. Furthermore,
using inhibitors of protein kinase R (PKR), a soluble dsRNA
sensor, they showed that IFN production could be ablated,
supporting a PKR involvement in the dsRNA response by pDCs.
These discrepancies may be species related or perhaps they
suggest that RIG-I andMDA5may play different roles in pDCs and
cDCs.3.2. Spatiotemporal engagement of Toll-like
receptor 7 and 9
Although TLR-7 and TLR-9 engagement, by their respective
ligands, leads to the expression of type I IFN in a MyD88-
dependent manner, their response, by which they produce IFN,
is not necessarily equivalent. For instance, Hilyer and coworkers
showed that in pDCs, TLR-9 engagement by CpG DNA results in
the expression of all forms of IFN; whereas, treatment of pDCs
with the TLR-7 agonist Imiquimod leads to activation of all
forms of type I IFN except IFN-α7 [40]. Although stimulation of
TLR-7 or TLR-9 leads to IFN and inflammatory cytokine
production, the spatiotemporal engagement of these receptors
determines the product of their activation [56,57]. Type A
CpGs, which activate TLR-9 and are retained in the early
endosomes, together with the MyD88-IRF-7 complex, induce
high IFN-α production from pDCs, but type A CpGs are weak
activators of TLR-9-dependent NF-κB signaling. In contrast,
type B CpGs, which are preferentially retained in late
endosomes, are weak activators of IFN but trigger a robust
inflammatory cytokine response. The ability of pDCs to retain
TLR-activating ligands is a principal factor that contributes to
their unique ability to mount a rapid and massive IFN response.
Additionally, while IRF-7 is expressed at low levels in most cells
and is only upregulated upon microbial infections, high-level
expression of IRF-7 is constitutive and unique to pDCs and
contributes significantly to their ability to mount a rapid IFN
response [58–60].4. Antigen presentation
4.1. Presentation of exogenous and
endogenous antigens
pDCs are widely accepted as “professional” antigen presenting
cells and their abilities in this regard have been comprehen-
sively reviewed by Villadangos and Young [61]; therefore, we
will briefly recapitulate some of their conclusions and address
current developments regarding this subject. As “professional”
APCs, cDCs have the capacity to capture, process, and present
antigens in order to activate naïve T cells, a process typically
referred to as “priming”. Exogenous antigens are internalized
specifically by phagocytosis and receptor-mediated endocyto-
sis or nonspecifically along with extracellular fluid in the
process of macropinocytosis [5]. Exogenous antigens can also
be internalized upon infection of the APC by a pathogen such as
a virus. Once taken up by the cDC, antigens are partially
digested and loaded onto MHCmolecules for presentation. The
Fig. 1 Activation of endosomal TLR-7 and TLR-9 in pDCs. The activation of TLR-7 or TLR-9 leads to recruitment of the myeloid
differentiation primary response protein 88 (MyD88) via its Toll/interleukin-1 (IL-1) receptor (TIR) domain. MyD88 recruits the
interleukin-1 receptor-associated kinase 4 (IRAK)-4, which in turn engages IRAK1 or IRAK2. Formation of the resultant complex promotes a
conformational change in the kinase domains of the IRAKs, leading to their autophosphorylation and subsequent activation. Activated
IRAK kinase complexes phosphorylate the TNF receptor associated factor 6 (TRAF6), which promotes the polyubiquitination of the
NF-kappa-B essential modulator (NEMO), as well as itself. Ubiquitinated NEMO then engages the nuclear factor kappa-B kinase subunit
alpha and beta (IKKα and β) to form the IκB kinase complex. IκB then liberates NF-κB dimers, leading to their translocation into the
nucleus promoding transcription of proinflammatory cytokines. TRAF6 can also activate the mitogen-activated protein kinases kinase
(MAPKK), which in turn activates mitogen-activated protein kinases (MAPKs), leading to the upregulation of B7 costimulatory molecules
(CD80, CD86). Conversely, TRAF6 can directly interact with IKKα, which phosphorylates IFN regulatory factor 7 (IRF-7), promoting its
translocation into the nucleus, thus initiating transcription of type I IFN. Alternatively, MyD88 engagement of phosphatidylinositide
3-kinases (PI3K) followed by protein kinase B (PKB), mammalian target of rapamycin (mTOR), and the adapter protein raptor, activates
IKKα and circumvents the IRAK complexes. Activation of TLRs in early endosomes favors expression of IFN whereas activation of TLRs in
late endosomes favors expression of inflammatory cytokines.
169presence of antigens bound to MHC class II, in conjunction with
T cell costimulatory molecules, is mandatory for the priming of
naïve T cells in the LNs. Consequently, the ability to upregulate
both MHC class II and T cell costimulatory molecules (such as
CD40) to prime naïve T cells defines a professional APC.
Accordingly, pDCs are clearly APCs, but they are distinctly
different from cDCs in their efficiency in priming naïve T cells.
Although pDCs have the capacity to prime naïve T cells, cDCs
are far more efficient in doing so [62,63]. Additionally, while
cDCs and pDCs efficientlymigrate to sites of infection, pDCs are
less proficient in making their way to the draining LNs [35,64].
Moreover, the few pDCs that do make their way to the draining
LNs appear to do so only at the late stages of infection [65].
This observation suggests that pDCs may have a more specific
role of antigen presentation at local sites of infection, where a
continual supply of antigen is available to populate newly
synthesized MHC II. The constitutive turnover of MHC II also
suggests that pDCs may be more efficient at presenting
endogenous antigens, which may be more available to newlysynthesized MHC class II. This idea is consistent with previous
reports that pDCs can induce tolerance through the induction
of regulatory T cells (Tregs) [66–68].4.2. Cross-presentation of antigens
Two characteristics that make cDCs exquisitely efficient at
activating T cells are first, their ability to take up a wide
variety of exogenous antigens from the extracellular environ-
ment and load the processed peptides on MHC class II and
second, their ability to present exogenous antigens loaded on
MHC class I to cytotoxic CD8 T cells (cross-presentation) [69].
The ability of pDCs to perform these functions is less firmly
established. So how close are pDCs to cDCs in this capacity?
Bastos-Amador et al. recently reported that human pDCs have
the ability to capture and present exosomes and apoptotic
bodies from Jurkat T cells [70]. These observations are
consistent with previous reports that identify pDCs as
170 V.C. Lombardi, S.F. Khaiboullinaphagocytic antigen-presenting cells essential for tolerance to
vascularized cardiac allografts in an animal model of organ
transplantation [71]. Additionally, immature pDCs are report-
ed to have the capacity to phagocytose and present
viral-derived antigens, resulting in naïve CD8+ T cell priming.
Hoeffel and colleagues reported that purified human pDCs
could cross-present vaccinal lipopeptides and HIV-1 antigens
from apoptotic cell to specific CD8+ T cells [72]. Also, in a set
of elegantly designed experiments, Tel et al. showed that
freshly isolated pDCs can cross-present exogenous antigens to
CD8+ T cells, although at a lower capacity than cDCs [73].
Previous studies have shown that pDCs have the capacity to
take up antibody-coupled antigens via their C-type lectin
DEC-205 receptor, their DC immunoreceptor, and their
BDCA-2 receptor [38,74,75]. In a separate report, Tel et al.
also showed that pDCs efficiently cross-present antigens to
both CD4+ and CD8+ T cells when directed to these same
receptors [76]. Additionally, Sandgren and colleagues report-
ed that pDCs efficiently capture recombinant HIV-1 Env
protein for antigen presentation via their CD4 receptor [77].
Taken together, these data imply that receptor specificity
may be requisite for the ability of pDCs to internalize and
(cross-) present a discrete class of exogenous antigens.
5. pDCs as a component of the gut-associated
lymphoid tissue
5.1. Localization of pDCs in the gut
The gut-associated lymphoid tissue (GALT) represents the
largest immune compartment in the body. In fact, it has been
estimated that more than 60% of all T-cells may reside within
the small intestine [78], emphasizing the potential contribu-
tion of the gut to systemic immunity. Although the role of T and
B cells in gut immunity and mechanisms by which they inhabit
the gut is well described, an understanding of the immunology
and contribution by pDCs is incomplete at best. Due to
limitations of access to biological materials, most of what we
know about pDC intestinal biology comes from studies con-
ducted using animal models. However, within certain limita-
tions, observations made using animal models are largely
consistent with those in humans.
As stated in Section 2.2, pDCs are clearly defined by their
unique expression of the C-type lectin receptor CD303 in
humans, whereas murine pDCs uniquely express the mouse
plasmacytoid dendritic cell antigen-1 (mPDCA-1) [27]. Al-
though the surface phenotype of peripheral pDCs and those
residing in the lymph nodes have been extensively character-
ized [36], pDCs associated with other tissues are less well
described. In the steady-state, pDCs are rare in most tissues
such as the skin, except at sites of infection or inflammation
[79,80], but are relatively abundant in the intestine where
they comprise up to 1% of total cells in the epithelium
(intraepithelial, IE) and the lamina propria (LP) [31]. The gut
microbiota plays an important role in maintaining intestinal
homeostasis; however, it is common for pathogenic organisms
to infect the intestinal tract and it is therefore important for
the immune system to discriminate commensal microbes from
pathogenic ones. It has been suggested that tissue-resident
DCs in the small intestine are trained by epithelial cells to be
tolerogenic to commensal microbes. In contrast, a pathogenassault on the epithelial cells will promote the infiltration of
pro-inflammatory DCs and elicit an immune response [81].
pDCs located in the Peyer's patch comprise a unique subset
that differs from pDCs located in other tissues, as they fail to
secrete type I IFN when stimulated with CpG DNA [82]. It is
believed that the local microenvironment of the Peyer's patch
promotes gut-pDC anergy and down-regulates their ability to
produce type I IFN when stimulated with TLR agonists.
Although these cells fail to produce IFN-α when stimulated
with TLR agonist, they do produce proinflammatory cytokines
as well as stimulate Th17 cell development [83]. The ability of
pDCs to play immunogenic or tolerogenic roles has also been
shown in other mucosal tissue, such as the lungs where
Lombardi et al. demonstrated that murine CD8α−β− pDCs are
immunogenic; however, CD8α+β− and CD8α+β+ pDCs exhibited
tolerogenic properties and effectively supported the conver-
sion of naïve CD4+ T cells into Foxp3+ Tregs [84]. The human
equivalent of the murine CD8α+β− and CD8α+β+ pDCs has yet
to be identified as human pDCs do not express the CD8
receptor [36].
5.2. Trafficking to the gut
The steady-state migration of pDCs from the periphery to the
intestine relies upon the expression of discrete homing
receptors. In contrast to intestinal T and B cells, which express
integrin CD103, intestinal pDCs typically do not, nor do they
express CCR7 (CD197), which is commonly observed on
lymphocytes found in peripheral lymphoid organs (Table 1).
Instead, intestinal pDCs express significant levels of β2-integrin
(CD18) and moderate levels of α4β7 integrin (LPAM-1) [31].
Additionally, about half of gut-associated pDCs express P-
selectin (CD62P). Also, the majority of intestinal pDCs in the
steady-state express the chemokine receptor CCR9 (CD199).
This receptor likely plays a critical role in the migration of pDCs
under inflammatory conditions as well. Wendland and co-
workers reported that more than 95% of pDCs isolated from
murine IE and LP express this receptor; however, it is relatively
rare on pDCs in the periphery. Consistent with a putative role
for CCR9 in the steady-state migration of pDCs to the gut, CCR9
knockout mice show a virtual absence of pDCs in the small
intestine, though adoptive transfer of pDCs fromwild typemice
into CCR9 knockout mice restores normal migration to the small
intestine [31]. Mizuno and colleagues reported that CCR9+ pDCs
reside preferentially in the small intestine, but not in the colon
[85]. They additionally reported that CCR9+ pDCs play a role of
central importance in immunological homeostasis of the small
intestine in that deficiency of CCR9+ pDCs induced exacerbation
of ileitis.
6. Gut associated pDCs and adaptive immunity
6.1. T cell independent activation of B cells by pDCs
and gut homeostasis
In humans, IgA is the most abundant antibody isotype found in
mucosal secretions and DCs play an important role in
promoting their expression [86]. The process whereby B cells
acquire the expression of IgA is called “class switching
recombination” and occurs via both T-cell-dependent (TD)
and T-cell-independent (TI) pathways [87–89]. The IgAs
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effective in neutralizing pathogens and their toxins. In
contrast, the IgAs produced via the TI pathways are of
low-affinity and presumably limit the adhesion of commensal
bacteria to intestinal epithelia without neutralizing them
[90]. Although both pathways can be activated through cDCs
interactions, Tezuka and coworkers reported that pDCs
contribute to the TI production of IgA by B cells of the GALT,
to a greater extent than cDCs [91]. They also reported that
gut-associated pDCs express significant amounts of a mem-
brane bound form of tumor necrosis factor ligand superfamily
member 13 (TNFSF13 or CD256) and the B-cell activating
factor (BAFF or CD257). Additionally, they demonstrated that
the expression of these ligands was upregulated by stromal
cell-derived type I IFN and that the expression was required
for IgA induction. Finally, they showed that in the mesenteric
lymph nodes, stromal cells exclusively expressed type I IFN in
the steady state as a result of TLR-dependent recognition of
commensal bacteria. In that stromal cell derived type I IFN
upregulates CD256 and CD257 and these ligands are necessary
for TI production of IgA, these data suggests that functional
pDCs and low-level expression of type I IFN by stromal cells in
response to commensal bacteria are important formaintaining
gut homeostasis.6.2. pDCs in oral tolerance
Oral tolerance is a form of acquired tolerance that results in
immune suppression of T cell-mediated delayed-type hyper-
sensitivity (DHT) reactions to ingested dietary or other
non-pathogenic environmental antigens [92]. Although the
immune system encounters a myriad of digested antigens and
gut-related bacteria, they rarely invoke an inflammatory
response. However, in light of the constant potential for orally
ingested and bacterial antigen exposure, maintaining proper
control of oral tolerance is critical for gut integrity. As an
example, when dysregulated, the resultant inflammatory
response to dietary antigens or gut microbiota is associated
with celiac disease and inflammatory bowel disease, respec-
tively [93–96].
The gut is replete with DCs, particularly in the mesenteric
lymph nodes and the liver as well as in the lamina propria and
the Peyer's patches of the gastrointestinal (GI) tract [97–100].
The unique environment of the GI tract allows DCs to interact
readily with antigens in intestinal lumen or antigens that have
transcytosed across intestinal epithelia. Indeed, Worbs et al.
reported that orally administered antigens are exclusively
recognized by the intestinal immune system and primarily in
the mesenteric lymph nodes [101]. In support of this assertion,
they observed complete loss of oral tolerance in mice following
mesenteric lymphadenectomy. For these reasons, a fundamen-
tal role for DCs in oral tolerance is not unexpected (reviewed by
Rescigno [102]). Multiple mechanisms have been described in
relation to the induction of oral tolerance; for example, the
activation of antigen-specific Tregs is primarily attributed to
CD103+ cDC in the lamina propria of mice, where these cells
express the tryptophan-degrading enzyme indoleamine 2,3-
dioxygenase (IDO) and have been shown to promote Foxp3+
Treg development via a TGF-β and retinoic acid (RA)-
dependent mechanism [103,104]. However, in humans, the
expansion of tolergenic DCs, which drive Treg development, isadditionally dependent on presence of thymic stromal
lymphopoietin [105]. Also, low-dose antigen feeding has been
reported to promote the expansion of CD4+CD25+ Tregs
[106,107] and Th3 cells [108], which, upon adoptive transfer,
can suppress inflammatory responses [109].
Oral tolerance can also be promoted through a mechanism
that results in the depletion of antigen-specific T cells or
though the inactivation of reactive T cells (anergy). Recent
evidence suggests that cytotoxic CD8+ T cells are important
contributors to diseases characterized by severe chronic GI
inflammation and dysregulation of tolerance such as celiac
disease and inflammatory bowel disease (IBD) [110,111]. Using
a model of allergic contact dermatitis and a classical model of
DTH, mediated by specific CD4+ T cells to ovalbumin, Goubier
et al. observed that antigen feeding prior to skin sensitization
induced tolerance and inhibited CD8+ T cell priming and
additionally prevented the development of delayed-type
contact hypersensitivity by a mechanism that involved both
Tregs and pDCs [112]. In a subsequent report, Dubois and
coworkers demonstrated that pDCs promoted the deletion of
Ag-specific CD8+ T cells in the GALT and that Treg inhibition of
residual effector T cell priming is both sequential and
complementary events that are mandatory for complete
ablation of systemic CD8+ T cell-mediated DTH responses to
orally administered antigens [113].
7. Gut-associated pDCs and human disease
7.1. Inflammatory bowel disease and other
autoimmune diseases
Over the past decade, it has been suggested that pDCs play a
role in the pathogenesis of autoimmune irritable bowel
diseases (IBDs) including Crohn's disease, and ulcerative
colitis (UC), although a consensus on this subject has not
been reached. Baumgart and coworkers observed an in-
crease in pDC numbers in the inflamed colonic mucosa and
mesenteric lymph nodes of subjects with IBD [114]. They
additionally reported that increased gut mucosa pDCs were
associated with a decrease in pDCs in the periphery of these
subjects [115] and that the decrease of pDCs in the
periphery directly correlated with the severity of disease
[115]. Interestingly, they also reported that pDCs in the
periphery of those with IBD upregulate the α4β7 integrin
receptor, which as stated above, is associated with migra-
tion to the gut and with a mature phenotype. Additionally, a
higher percentage of circulating pDCs were reported to
express CD40 and CD86 in cases with IBD as compared to
healthy controls [114,115]. Lastly, they observed that
expression of TNFα, IL6, and CXCL8 was significantly higher
in pDCs from cases with IBD compared to controls [114]. In
contrast, Middel and colleagues reported that they observed
no differences in pDC numbers in colonic tissue from Crohn's
disease cases and controls [116]; and similar observations
were reported by Mannon et al. [117]. Further studies will be
necessary to resolve these discrepancies; however, these
data raise the possibility of pDC involvement in autoimmune
gut pathology. We have recently reported an increased
infiltration of pDCs in the duodenum of cases with symptoms
consistent with myalgic encephalomyelitis [118], a disease
that often presents as a comorbid condition of irritable
172 V.C. Lombardi, S.F. Khaiboullinabowel syndrome [119]. The increase in duodenum pDCs may
be the result of GI inflammation or infection; however,
additional studies are currently being conducted to address
this observation.
Associations with pDCs and several other autoimmune
diseases have been reported including multiple sclerosis (MS),
psoriasis, type 1 diabetes, Sjögren's syndrome, rheumatoid
arthritis (RA) and systemic lupus erythematosus (SLE)
[120–125]. For example, in most cases of SLE, an over-
expression of type I IFN is observed which correlates with
disease activity and severity [126]. Lande and coworkers
identified immunogenic complexes composed of neutrophil-
derived antimicrobial peptides and self-DNA in the sera of SLE
cases [125]. They further reported that these complexes
activate pDCs via TLR-9 leading to the upregulation of type I
IFN and the development of autoantibodies. Associations of
autoimmunity and the dysregulation of type I IFN expression
have prompted researchers to target pDCs for the treatment
of diseases such as SLE and RA. Barrat and coworkers observed
a significant reduction in autoantibodies, a decrease in end-
organ damage and increased survival in lupus-prone mice
treated with the specific TLR-7 and 9 inhibitor IRS 954 [127]. In
another study, Laio et al. observed that the TLR-9 inhibitor
RO9021 suppressed type I IFN expression as well as the
progression of arthritis in a mouse model of collagen-induced
arthritis [128]. In contrast to SLE, subjects with MS are often
reported to have a suboptimal IFN response [129] and many of
those individuals have been effectively treated with type I IFN
since the early 1980's [130].
Although a comprehensive review of pDCs and autoimmu-
nity is beyond the scope of this review, we would refer the
reader to the recent publication of Ganguly et al. [131] for a
comprehensive review of pDCs and their role in autoimmunity.7.2. Redistribution of pDCs to the gut in HIV/AIDS
cases
Previous studies have demonstrated that the GI tract is
preferentially and significantly affected during the course of
HIV infection (reviewed by Brenchley and Douek [132]).
Indeed, histological abnormalities in gut tissue of HIV cases
were first described by Kolter and colleagues in 1984 [133]
and subsequent studies have revealed a decreased regener-
ative capacity of the gut epithelium and increased mucosal
permeability in HIV cases [134–136]. Additionally, depletion
of CD4+ T cells is found to be a characteristic marker of HIV
infection [137] and is only partially restored by highly active
antiretroviral therapy (HAART) [138–141]. Importantly,
studies using rhesus macaques have confirmed that the
GALT is the principle site of HIV replication and occurs early
in the course of infection [142].
pDCs express the CD4 receptor, as well as the CCR5 and
CXCR4 co-receptors, making them susceptible to HIV. Their
expression also suggests why pDCs are more susceptible than
cDCs to HIV [143,144]. HIV is typically delivered to pDCs by
CD4+ T cells and activation of the pDC by CD40 ligand (also
delivered by the CD4+ T cell), promotes viral replication
[143]. Infected, pDCs may potentially play a role in viral
dissemination since they readily transmit HIV to CD4+ T cells
in vitro, and such transmission is also augmented by CD40
ligand activation [145,146].Studies of the pDC numbers in the blood of HIV cases
demonstrate a progressive depletion of these cells, which
correlates with plasma viral load [146–150]. Similar data were
shown in the blood of macaques infected with simian immune
deficiency virus (SIV) where the number of pDCs was reduced
3-fold [149]. Remarkably, circulating pDCs were reported to
express the gut-homing marker α4β7, suggesting pDCs were
primed formigration into the gut. Subsequent evaluation of the
rectal tissue of HIV infected animals revealed a fourfold
increase in the number of pDCs as compared to naïve animals.
These data support the hypothesis that the loss of pDCs in the
periphery was a result of their redistribution into the gut. In
further support of this, Li and colleagues have demonstrated a
fourfold increase in pDC accumulation in jejunum, colon, and
gut-draining LNs of SIV infected rhesus macaques [151]. At the
same time there was no pDC accumulation in the liver and
peripheral LNs. Similar distributions of pDCs have been
observed in HIV cases. For example, increased pDC accumula-
tion was detected in the terminal ileum of HIV infected cases
by Lehmann and colleagues [152]. Tissue homingwas explained
by significant upregulation of the gut-homing receptor CD103
as compared to uninfected controls. Indeed, HIV infection
appears to dictate pDC migration exclusively into the gut and
this migration is determined by the expression of gut homing
receptors. The mechanism responsible for the upregulation of
gut homing receptors in HIV cases has yet to be determined;
however, our initial concept of HIV as a disease of CD4 T cells
must now be reevaluated, and equally considered a disease of
the gut involving the redistribution and dysregulation of pDCs.
8. Concluding remarks
pDCs are relatively recent additions to the field of immunolog-
ical research; however, their significance is being realized at a
prodigious rate. Through the engagement of TLR-7 and TLR-9
by ssRNA and CpG DNA respectively, they produce substantially
more type I IFN than any other cell. It is because of these
pattern recognition receptors that their involvement in the
innate antiviral responsewas initially considered their principal
function, and indeed, their role in pathogen response cannot
be disputed. Nevertheless, they are now being appreciated for
their involvement in many other areas, including tolerance
induction and their contribution to human diseases such as
autoimmunity and HIV/AIDS. Most of our current understanding
of pDC biology has been conducted using pDCs derived from
whole blood or from the spleen of mice. As a result, the biology
of gut-associated pDCs is largely unexplored, but current
research suggests that these cells likely play a critical role in
many aspects of immunity and many exciting and undiscovered
things await our investigation.
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